Outcome of multimodal therapy in operated acromegalic patients, a study in 115 patients

Clinical Endocrinology

Volumn 78, Issue 2, 2013, Pages 263-270

  Albarel, Frédérique ^a,b   Castinetti, Frédéric ^a,b   Morange, Isabelle ^a,b   Conte Devolx, Bernard ^a,b   Gaudart, Jean ^c   Dufour, Henry ^d   Brue, Thierry ^a,b  

^a University of Mediterranée   (France)

^b TIMONE HOSPITAL   (France)

^c AIX MARSEILLE UNIV   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; CABERGOLINE; GLUCOSE; GROWTH HORMONE; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADRENAL INSUFFICIENCY; ADULT; ARTICLE; CANCER INVASION; CANCER RADIOTHERAPY; CEREBROSPINAL FLUID RHINORRHEA; DIABETES INSIPIDUS; DISEASE CONTROL; DISEASE SEVERITY; FEMALE; FERTILIZATION IN VITRO; FOLLOW UP; FRANCE; GAMMA KNIFE RADIOSURGERY; GLUCOSE BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HYPERPROLACTINEMIA; HYPONATREMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NEURALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RETROSPECTIVE STUDY; SINUSITIS; SURGEON; TRANSSPHENOIDAL SURGERY; TREATMENT DURATION; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

ACROMEGALY; ADENOMA; ADULT; AGED; AGED, 80 AND OVER; DOPAMINE AGONISTS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SOMATOSTATIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84872119180     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2012.04492.x     Document Type: Article

References (34)

1. Holdaway, I.M., &, Rajasoorya, C., (1999) Epidemiology of acromegaly. Pituitary, 2, 29-41.
2. Sanno, N., Teramoto, A., Osamura, R.Y., et al,. (2003) Pathology of pituitary tumors. Neurosurgery Clinics of North America, 14, 25-39.
3. Chanson, P., &, Salenave, S., (2008) Acromegaly. Orphanet Journal of Rare Disease, 3, 17.
4. Melmed, S., Colao, A., Barkan, A., et al,. (2009) Guidelines for acromegaly management: an update. Journal of Clinical Endocrinology and Metabolism, 94, 1509-1517.
5. Holdaway, I.M., Bolland, M.J., &, Gamble, G.D., (2008) A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. European Journal of Endocrinology, 159, 89-95.
6. Kauppinen-Makelin, R., Sane, T., Reunanen, A., et al,. (2005) A nationwide survey of mortality in acromegaly. Journal of Clinical Endocrinology and Metabolism, 90, 4081-4086.
7. Giustina, A., Barkan, A., Casanueva, F.F., et al,. (2000) Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism, 85, 526-529.
8. Giustina, A., Chanson, P., Bronstein, M.D., et al,. (2010) A consensus on criteria for cure of acromegaly. Journal of Clinical Endocrinology and Metabolism, 95, 141-3148.
9. Melmed, S., Casanueva, F., Cavagnini, F., et al,. (2005) Consensus statement: medical management of acromegaly. European Journal of Endocrinology, 153, 737-740.
10. Giustina, A., Bronstein, M.D., Casanueva, F.F., et al,. (2011) Current management practices for acromegaly: an international survey. Pituitary, 14, 125-133.
11. Freda, P.U., (2009) Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? Clinical Endocrinology, 71, 166-170.
12. Trainer, P.J., Barth, J., Sturgeon, C., et al,. (2006) Consensus statement on the standardisation of GH assays. European Journal of Endocrinology, 155, 1-2.
13. Mickey, R.M., &, Greenland, S., (1989) The impact of confounder selection criteria on effect estimation. American Journal of Epidemiology, 129, 125-137.
14. Beauregard, C., Truong, U., Hardy, J., et al,. (2003) Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clinical Endocrinology, 58, 86-91.
15. Biermasz, N.R., van Dulken, H., &, Roelfsema, F., (2000) Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. Journal of Clinical Endocrinology and Metabolism, 85, 4596-4602.
16. Swearingen, B., Barker, 2nd F.G., Katznelson, L., et al,. (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism, 83, 3419-3426.
17. Biermasz, N.R., Dekker, F.W., Pereira, A.M., et al,. (2004) Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. Journal of Clinical Endocrinology and Metabolism, 89, 2789-2796.
18. Carmichael, J.D., Bonert, V.S., Mirocha, J.M., et al,. (2009) The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 94, 523-527.
19. Fahlbusch, R., Honegger, J., &, Buchfelder, M., (1997) Evidence supporting surgery as treatment of choice for acromegaly. The Journal of Endocrinology, 155 (Suppl 1), 53-55.
20. Kaltsas, G.A., Isidori, A.M., Florakis, D., et al,. (2001) Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. Journal of Clinical Endocrinology and Metabolism, 86, 1645-1652.
21. Trepp, R., Stettler, C., Zwahlen, M., et al,. (2005) Treatment outcomes and mortality of 94 patients with acromegaly. Acta Neurochirurgica (Wien), 147, 243-251.
22. Jane Jr, J.A., Starke, R.M., Elzoghby, M.A., et al,. (2011) Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. Journal of Clinical Endocrinology and Metabolism, 96, 2732-2740.
23. Hofstetter, C.P., Mannaa, R.H., Mubita, L., et al,. (2010) Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas. Neurosurgical Focus, 29, E6.
24. Shimon, I., Cohen, Z.R., Ram, Z., et al,. (2001) Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery, 48, 1239-1243.
25. Freda, P.U., Wardlaw, S.L., &, Post, K.D., (1998) Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. Journal of Neurosurgery, 89, 353-358.
26. Espinosa-de-Los-Monteros, A.L., Sosa, E., Cheng, S., et al,. (2006) Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status. Clinical Endocrinology, 64, 245-249.
27. Minniti, G., Jaffrain-Rea, M.L., Esposito, V., et al,. (2003) Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature. Endocrine-Related Cancer, 10, 611-619.
28. Parfitt, V.J., Flanagan, D., Wood, P., et al,. (1998) Outpatient assessment of residual growth hormone secretion in treated acromegaly with overnight urinary growth hormone excretion, random serum growth hormone and insulin like growth factor-1. Clinical Endocrinology, 49, 647-652.
29. Abosch, A., Tyrrell, J.B., Lamborn, K.R., et al,. (1998) Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. Journal of Clinical Endocrinology and Metabolism, 83, 3411-3418.
30. Bourdelot, A., Coste, J., Hazebroucq, V., et al,. (2004) Clinical, hormonal and magnetic resonance imaging (MRI) predictors of transsphenoidal surgery outcome in acromegaly. European Journal of Endocrinology, 150, 763-771.
31. Kreutzer, J., Vance, M.L., Lopes, M.B., et al,. (2001) Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. Journal of Clinical Endocrinology and Metabolism, 86, 4072-4077.
32. Tomlinson, J.W., Holden, N., Hills, R.K., et al,. (2001) Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet, 357, 425-431.
33. Florio, T., Barbieri, F., Spaziante, R., et al,. (2008) Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocrine Related-Cancer, 15, 583-596.
34. Petersenn, S., Schopohl, J., Barkan, A., et al,. (2010) Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. Journal of Clinical Endocrinology and Metabolism, 95, 2781-2789.